MIRM (Mirum Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

MIRM (Mirum Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

Mkt Cap$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$521M

Net Income (TTM)-$23M

EPS (TTM)-$0.49

Free Cash Flow (TTM)$55M

Gross Margin80.8%

Op. Margin-4.2%

Net Margin-4.5%

FCF Margin10.5%

P/S Ratio (TTM)8.7x

P/E Ratio (TTM)—

YoY Rev Growth+54.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$32M	$27M	-$27M
Q2 23	$37M	$31M	-$24M
Q3 23	$48M	$37M	-$25M
Q4 23	$70M	$45M	-$33M
Q1 24	$69M	$51M	-$26M
Q2 24	$78M	$58M	-$24M
Q3 24	$90M	$70M	-$13M
Q4 24	$99M	$77M	-$24M
Q1 25	$112M	$89M	-$15M
Q2 25	$128M	$104M	-$5M
Q3 25	$133M	$107M	$3M
Q4 25	$149M	$121M	-$5M

Valuation

Quarter	P/S	P/E
Q1 23	47.3x	—
Q2 23	39.1x	—
Q3 23	31.3x	—
Q4 23	24.3x	—
Q1 24	20.2x	—
Q2 24	17.1x	—
Q3 24	14.7x	—
Q4 24	13.4x	—
Q1 25	11.9x	—
Q2 25	10.5x	—
Q3 25	9.6x	—
Q4 25	8.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$19M	-$34M
Q2 23	-$17M	-$17M
Q3 23	-$18M	-$18M
Q4 23	-$17M	-$22M
Q1 24	$15M	$15M
Q2 24	-$4M	-$15M
Q3 24	$4M	-$6M
Q4 24	-$5M	-$5M
Q1 25	-$2M	-$2M
Q2 25	$12M	$12M
Q3 25	$40M	$39M
Q4 25	$6M	$5M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$15M
Q2 23	$68K
Q3 23	$0
Q4 23	$5M
Q1 24	$13K
Q2 24	$11M
Q3 24	$10M
Q4 24	$20K
Q1 25	$41K
Q2 25	$126K
Q3 25	$187K
Q4 25	$600K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+145.1%	+28.7%
Q2 23	+114.5%	+26.3%
Q3 23	+154.1%	+41.1%
Q4 23	+149.2%	+64.6%
Q1 24	+119.1%	+62.9%
Q2 24	+107.7%	+65.3%
Q3 24	+89.4%	+41.4%
Q4 24	+42.9%	+21.0%
Q1 25	+61.2%	+32.5%
Q2 25	+64.1%	+30.0%
Q3 25	+47.2%	+26.5%
Q4 25	+49.8%	+24.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	27.1%
Q2 23	$8M	22.3%
Q3 23	$8M	17.6%
Q4 23	$10M	14.0%
Q1 24	$11M	16.5%
Q2 24	$12M	15.2%
Q3 24	$12M	13.2%
Q4 24	$13M	13.3%
Q1 25	$16M	14.2%
Q2 25	$18M	14.5%
Q3 25	$18M	13.6%
Q4 25	$19M	12.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$24M	—	—	$30M
Q2 23	$22M	$33M	—	—
Q3 23	$26M	—	—	$37M
Q4 23	$31M	—	—	$46M
Q1 24	$32M	—	—	$46M
Q2 24	$33M	$41M	$8M	—
Q3 24	$32M	—	—	$51M
Q4 24	$44M	—	—	$57M
Q1 25	$46M	—	—	$58M
Q2 25	$46M	—	—	$63M
Q3 25	$43M	—	—	$62M
Q4 25	$51M	—	—	$74M

Revenue Segments

Quarter	License	Product	License and Other Revenue
Q1 23	$3M	$29M	—
Q2 23	$5M	$32M	—
Q4 23	—	$70M	—
Q1 24	—	$69M	$305K
Q2 24	—	$78M	$115K
Q3 24	—	$90M	$75K
Q1 25	—	$112M	—
Q2 25	—	$128M	—
Q3 25	—	$133M	—
Q4 25	—	$149M	—

Revenue by Geography

Quarter	Rest Of World	United States
Q1 24	$13M	$56M
Q2 24	$13M	$65M
Q3 24	$16M	$74M
Q1 25	$25M	$87M
Q2 25	$32M	$96M
Q3 25	$29M	$104M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$49M	$83M	$132M
Q2 23	$297M	$33M	$330M
Q3 23	$303M	$3M	$306M
Q4 23	$286M	$0	$286M
Q1 24	$303M	$0	$303M
Q2 24	$233M	$45M	$278M
Q3 24	$223M	$61M	$284M
Q4 24	$223M	$58M	$280M
Q1 25	$212M	$66M	$278M
Q2 25	$228M	$76M	$305M
Q3 25	$282M	$94M	$376M
Q4 25	$297M	$87M	$383M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	38M	+0.4%
Q2 23	38M	+1.1%
Q3 23	41M	+7.9%
Q4 23	47M	+13.7%
Q1 24	47M	+0.4%
Q2 24	47M	+0.7%
Q3 24	48M	+1.2%
Q4 24	48M	+1.2%
Q1 25	49M	+1.1%
Q2 25	50M	+1.7%
Q3 25	57M	+14.6%
Q4 25	50M	-11.9%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	$0	33
FY 20	$0	68
FY 21	$140K	137
FY 22	$393K	196
FY 23	$706K	264
FY 24	$1M	322
FY 25	$10K	54K